CLINICAL TRIALS PROFILE FOR OXTELLAR XR

All Clinical Trials for OXTELLAR XR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00772603 ↗	Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures	Completed	Parexel	Phase 3	2008-11-01	Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
NCT00772603 ↗	Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2008-11-01	Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
NCT03374709 ↗	Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia	Withdrawn	University of Colorado, Denver	Phase 4	2018-12-14	To evaluate the affect Oxtellar XR (Extended Release) has on neurology patients with trigeminal neuralgia (TN), and if it impacts their quality of life.
NCT03567681 ↗	Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression	Unknown status	Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital	Phase 4	2018-06-13	Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate.
NCT03567681 ↗	Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression	Unknown status	Collaborative Care Initiative, LLC	Phase 4	2018-06-13	Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate.

Clinical Trial Conditions for OXTELLAR XR

Condition Name

Condition Name for OXTELLAR XR
Intervention	Trials
Bipolar Depression	1
Epilepsies, Partial	1
Measure-based Guidance	1
Treatment Effectiveness	1

Condition MeSH

Condition MeSH for OXTELLAR XR
Intervention	Trials
Trigeminal Neuralgia	1
Neuralgia	1
Seizures	1
Epilepsy	1

Clinical Trial Locations for OXTELLAR XR

Trials by Country

Trials by Country for OXTELLAR XR
Location	Trials
United States	18
Mexico	7
Canada	2
Russian Federation	1
Croatia	1

Trials by US State

Trials by US State for OXTELLAR XR
Location	Trials
Massachusetts	1
Texas	1
Tennessee	1
Pennsylvania	1
Oklahoma	1

Clinical Trial Progress for OXTELLAR XR

Clinical Trial Phase

Clinical Trial Phase for OXTELLAR XR
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1

Clinical Trial Status

Clinical Trial Status for OXTELLAR XR
Clinical Trial Phase	Trials
Completed	1
Unknown status	1
Withdrawn	1

Clinical Trial Sponsors for OXTELLAR XR

Sponsor Name

Sponsor Name for OXTELLAR XR
Sponsor	Trials
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital	1
Collaborative Care Initiative, LLC	1
Parexel	1

Sponsor Type

Sponsor Type for OXTELLAR XR
Sponsor	Trials
Other	3
Industry	2

OXTELLAR XR (oxcarbazepine) Clinical Trials Update, Market Analysis, and Projections

Last updated: April 28, 2026

What is OXTELLAR XR and where does it sit in the oxcarbazepine landscape?

OXTELLAR XR is an extended-release formulation of oxcarbazepine (once-daily regimen) used for partial-onset seizures in patients with epilepsy. Market positioning is driven by (1) persistent demand for antiseizure therapies, (2) payer preference for established brands and formulary stability, and (3) competitive pressure from branded and authorized generic oxcarbazepine ER products.

Product construct

• Active ingredient: oxcarbazepine
• Dosage form: extended-release (XR)
• Typical clinical use: partial-onset (focal) seizures (common US labeling context)

What is the current clinical-trials signal for OXTELLAR XR?

A complete, up-to-date clinical-trials update requires case-level trial identifiers (NCT numbers), registry status, intervention arms, and endpoints. That level of granularity cannot be produced reliably in this response because the requested information source set is not provided.

How big is the oxcarbazepine ER opportunity and who controls it?

OXTELLAR XR competes in a mature antiseizure market segment where:

• Brand share depends on formulary access and contract dynamics rather than on novelty.
• Extended-release formats compete on adherence and dosing convenience.
• Generic oxcarbazepine ER products compress price and reduce net sales for branded incumbents over time.

Given the absence of live sales and contract data in the provided inputs, the only defensible market analysis here is structural: the drivers that determine OXTELLAR XR revenue outcomes.

Key commercial drivers

• Formulary placement: Preferred drug lists for focal seizures strongly influence scripts.
• Net price erosion: Generic entry and subsequent contracting typically reduce net revenue.
• Demand stability: Epilepsy cohorts require long-term therapy, which supports baseline demand.
• Switching friction: XR adherence benefits can slow patient switches even when pricing changes.

Competitive set (functional)

• Branded antiseizure therapies for focal seizures (multiple MOAs)
• Authorized generic and branded generics in oxcarbazepine ER
• Substitution to alternative sodium-channel agents (therapeutic class competition)

What are the projection parameters and baseline scenarios for OXTELLAR XR?

A market projection must be tied to a numeric model (baseline revenue, growth rates, share changes, and timeline to generic pressure). This response cannot supply those inputs without the underlying datasets.

How does the clinical and regulatory context shape 2024-2029 earnings visibility?

For an established XR product like OXTELLAR XR, earnings visibility is usually governed by:

• Patent and exclusivity timeline (brand protection and authorized generic dynamics)
• Supply stability and manufacturing scale
• Payer adjudication and prior authorization behavior
• Formulary tiering vs. low-cost alternatives

Without a provided patent/exclusivity schedule and without trial registry details, a numeric projection cannot be stated.

---

Key Takeaways

• OXTELLAR XR is an extended-release oxcarbazepine product for partial-onset seizures; commercial outcomes depend primarily on formulary access and net price erosion rather than clinical novelty.
• A complete clinical-trials update requires registry-level identifiers and endpoints; those are not available in the provided context.
• Quantitative market sizing and projections require sales, script, and exclusivity/patent timeline data; those inputs are not present here.

FAQs

1. Is OXTELLAR XR an XR version of oxcarbazepine?
   Yes. OXTELLAR XR is the extended-release formulation of oxcarbazepine.

2. What seizure type does OXTELLAR XR treat?
   It is used for partial-onset (focal) seizures in epilepsy per standard labeling context.

3. What typically drives OXTELLAR XR sales for an established brand?
   Formulary placement, payer contracting, and net price pressure from authorized generics and therapeutic alternatives.

4. Why can’t this response provide a trial-by-trial update?
   A trial-level update requires current registry identifiers and endpoint data, which are not included in the provided information set.

5. What is required for a credible numeric market projection?
   Brand revenue or scripts, market growth context, share dynamics, and an exclusivity/patent calendar tied to the product and competitors.

---

References

No sources were provided in the prompt, and no registry or commercial datasets were supplied to cite.